Contribute Try STAT+ Today

The Food and Drug Administration has placed a clinical hold on one of Cellectis’s off-the-shelf CAR-T trials after one patient died of cardiac arrest, a worrying development for a technology thought to be safer than the approved alternative.

Cellectis’s treatment, UCARTCS1A, is derived from T cells provided by healthy donors, more practical and potentially less dangerous than traditional CAR-T therapies made from patients’ own immune cells. But the patient death, which emerged in a multiple myeloma study, suggests off-the-shelf CAR-T could carry risks of its own.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy